Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 22, 2024
Daily News
October 22, 2024
- Academic Societies Urge COVID-19 Vaccinations, Deny Kostaive “Shedding”
October 22, 2024
- Takeda to Offer Buyout Package from December as Part of Reorganization
October 22, 2024
- LDP’s Hashimoto Makes Rare Speech on Drug Prices amid Close Race in Okayama
October 22, 2024
- Aculys Pharma’s Pitolisant Nets Positive Data in Japan PIII
October 22, 2024
- Astellas’ Gastric Cancer Med Vyloy Approved in US after Re-Filing
October 22, 2024
- Pfizer Veteran Pullicino to Lead Novartis Japan
October 22, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…